Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.

ABSTRACT: Homozygous familial hypercholesterolemia (HoFH) is a life-threatening Mendelian disorder with a mean life expectancy of 33 years despite maximally tolerated standard lipid-lowering therapies. This disease is an ideal candidate for gene therapy, and in the last few years, a number of exciting developments have brought this approach closer to the clinic than ever before. In this review, we discuss in detail the most advanced of these developments, a recombinant adeno-associated virus (AAV) vector carrying a low-density lipoprotein receptor (LDLR) transgene which has recently entered phase 1/2a testing. We also review ongoing development of approaches to enhance transgene expression, improve the efficiency of hepatocyte transduction, and minimize the AAV capsid-specific adaptive immune response. We include a summary of key gene therapy approaches for HoFH in pre-clinical development, including RNA silencing of t?he gene encoding HMG-CoA reductase (HMGCR) and induced pluripotent stem cell transplant therapy.

SUBMITTER: Ajufo E 

PROVIDER: S-EPMC5609810 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature